Cephalexin and Apixaban (Eliquis) Interaction
There is no significant drug interaction between cephalexin and apixaban (Eliquis) that would require dose adjustment or medication changes in most patients.
Pharmacological Considerations
- Apixaban (Eliquis) is a direct oral anticoagulant (DOAC) that is primarily metabolized via the liver through cytochrome P450 3A4-dependent pathways, with approximately 27% eliminated through renal excretion 1
- Apixaban is a substrate for both CYP3A4 enzymes and P-glycoprotein (P-gp)/BCRP transporters, making it susceptible to interactions with drugs that affect these pathways 1, 2
- Cephalexin is a first-generation cephalosporin antibiotic that is not known to significantly inhibit or induce CYP3A4 or P-gp transporters 3
- Significant interactions with apixaban typically occur with medications that are moderate to strong inhibitors of both CYP3A4 and P-gp pathways, which cephalexin is not 1, 2
Safety Profile
- Unlike other antibiotics such as trimethoprim/sulfamethoxazole, ciprofloxacin, levofloxacin, metronidazole, fluconazole, azithromycin, and clarithromycin that are considered high-risk for interaction with anticoagulants, cephalexin is classified as a low-risk antibiotic 4
- A retrospective cohort study of veterans on warfarin specifically identified cephalexin as a low-risk antibiotic for bleeding complications when co-administered with anticoagulants 4
- No drug interactions between cephalexin and anticoagulants were reported in clinical trials of cephalexin 3
Risk Factors That May Increase Bleeding Risk
While the direct interaction between cephalexin and apixaban is minimal, certain patient factors may increase overall bleeding risk:
- Severe renal impairment (CrCl <15 mL/min) - apixaban should be used with caution in these patients regardless of antibiotic use 5
- Hepatic impairment - apixaban metabolism may be affected in patients with liver disease 1, 6
- Advanced age - older patients may have increased risk of bleeding complications with any anticoagulant 7
- Concomitant use of other medications that affect hemostasis (e.g., NSAIDs, antiplatelet drugs) 8
Monitoring Recommendations
- Regular monitoring for signs of unusual bleeding or bruising should continue as standard practice for patients on apixaban, regardless of cephalexin use 2
- Unlike high-risk antibiotics that warrant INR monitoring within 3-14 days of co-prescription (which was shown to decrease bleeding risk), this is not necessary with cephalexin 4
- Monitor for potential side effects specific to each medication 2
Management Recommendations
- No dose adjustment of either medication is required when used concurrently 2, 3
- For patients undergoing invasive procedures, follow standard protocols for temporary discontinuation of apixaban based on bleeding risk of the procedure 9
- For low bleeding risk procedures, apixaban can be discontinued the morning of the day before the procedure (if twice daily regimen) or two days before (if once daily evening regimen) 9
- For high bleeding risk procedures, apixaban should be discontinued three days before the procedure 9
Special Considerations
- In patients with severe renal impairment (CrCl <15 mL/min), the European Medicines Agency recommends using the lower 2.5 mg dose of apixaban, as this was associated with lower bleeding risk compared to the 5 mg dose 7
- Patients with moderate to severe hepatic impairment may require closer monitoring due to potential alterations in apixaban metabolism 1, 6
In conclusion, cephalexin can be safely co-administered with apixaban in most patients without dose adjustments or additional monitoring beyond standard care.